Cash, cash equivalents, and marketable securities were $117.9 million as of December 31, 2023, compared to $133.6 million as of September 30, 2023. In January 2024, the Company announced that it extended its projected cash runway into the second half of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIGL:
- Vigil Neuroscience appoints Kaufmann as Chief Medical Officer
- Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
- VIGL Earnings this Week: How Will it Perform?
- Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
- Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days